论文部分内容阅读
目的探讨恩替卡韦联合胸腺素治疗代偿期乙型肝炎肝硬化患者的临床疗效。方法选取本院收治的代偿期乙型肝炎肝硬化患者84例,随机分为恩替卡韦治疗37例和恩替卡韦联合胸腺素治疗47例。比较两组患者治疗前后ALT、INR、TBIL、ALB、肝弹性值、HBV DNA水平变化。结果恩替卡韦组治疗前和52周末血清ALT分别为(86.5±66.7)IU/L和(27.1±12.2)IU/L(P<0.05);联合用药组治疗前和52周ALT分别为(87.3±66.9)IU/L和(33.1±11.8)IU/L(P<0.05);恩替卡韦组治疗前和52周ALB分别为(42.5±5.6)g/L和(45.6±4.2)g/L(P<0.05);两组治疗后肝弹性值均显著下降,但两组无显著性相差(P>0.05);在治疗52周末,在37例恩替卡韦治疗患者中,17例(45.9%)出现HBV DNA低于检测下限,而47例联合用药组患者中有32例(68.1%)出现HBV DNA低于检测下限,两组有统计学差异(P<0.05)。结论恩替卡韦联合胸腺素治疗能有效地抑制HBV DNA复制,改善肝纤维化程度。结论恩替卡韦联合胸腺素治疗乙型肝炎肝硬化有效。
Objective To investigate the clinical efficacy of entecavir combined with thymosin in the treatment of patients with decompensated hepatitis B cirrhosis. Methods Eighty-four patients with decompensated hepatitis B cirrhosis admitted in our hospital were randomly divided into entecavir 37 cases and entecavir thymosin 47 cases. The changes of ALT, INR, TBIL, ALB, hepatic elasticity and HBV DNA levels before and after treatment were compared between the two groups. Results The serum ALT before and 52 weeks after entecavir treatment were (86.5 ± 66.7) IU / L and (27.1 ± 12.2) IU / L respectively (P <0.05). The ALT before and 52 weeks after entecavir treatment were (87.3 ± 66.9) ) And IU / L (33.1 ± 11.8) IU / L, respectively (P <0.05). The levels of ALB in entecavir group before and 52 weeks were (42.5 ± 5.6) g / L and ). After treatment, the liver elasticity value decreased significantly in both groups, but there was no significant difference between the two groups (P> 0.05). Among the 37 entecavir-treated patients, 17 cases (45.9%) had HBV DNA lower than The lower limit of detection was detected in 32 patients (68.1%) in the 47 combination groups. HBV DNA was lower than the lower limit of detection, with statistical significance (P <0.05). Conclusion Entecavir combined with thymosin can effectively inhibit HBV DNA replication and improve the degree of liver fibrosis. Conclusion Entecavir combined with thymosin is effective in treating hepatitis B cirrhosis.